The role of aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease.

Published on Oct 2, 2021in European Journal of Preventive Cardiology7.804
· DOI :10.1093/EURJPC/ZWAB149
Johann Auer (Paracelsus Private Medical University of Salzburg), Gudrun Lamm1
Estimated H-index: 1
(UHSA: University of Health Sciences Antigua)
Sources
Abstract
References21
Newest
Source
#1Russell V. Luepker (UMN: University of Minnesota)H-Index: 98
#2Niki C. Oldenburg (UMN: University of Minnesota)H-Index: 10
Last. Sue Duval (UMN: University of Minnesota)H-Index: 55
view all 7 authors...
Introduction Daily aspirin use for primary cardiovascular disease prevention is common among adults. Numerous clinical trials observe reduced cardiovascular disease with regular low-dose aspirin. The U.S. Preventive Services Task Force in 2016 published guidelines for aspirin use, but controversy exists about the side effects, and overuse or underuse may be common despite the guidelines. Using the Task Force recommendations, this paper describes the prevalence of appropriate aspirin use and phys...
Source
#1Ezimamaka Ajufo (UTSW: University of Texas Southwestern Medical Center)H-Index: 4
#2Colby Ayers (UTSW: University of Texas Southwestern Medical Center)H-Index: 55
Last. Amit Khera (UTSW: University of Texas Southwestern Medical Center)H-Index: 76
view all 7 authors...
Importance Higher coronary artery calcium (CAC) identifies individuals at increased atherosclerotic cardiovascular disease (ASCVD) risk. Whether it can also identify individuals likely to derive net benefit from aspirin therapy is unclear. Objective To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds. Design, Setting, and Participants Prospective population-based cohort study of Dallas Heart Study participants, f...
Source
Rates of thrombosis and bleeding episodes are both increased in patients with advanced chronic kidney disease (CKD). The pathogenic mechanisms of thrombosis in these patients include platelet activation, increased formation of platelet-leukocyte conjugates, and platelet-derived microparticles, as well as effects of uremic toxins on platelets. On the other side of the coin, platelet hyporeactivity mediated by uremic toxins and anemia contributes to the increased bleeding risk in advanced CKD. Pla...
Source
Background and Purpose— The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations in a single document for clinicians caring for adult patients with acute art...
Source
Acute kidney injury (AKI), mostly defined as a rise in serum creatinine concentration of more than 0.5 mg/dl, is a common, serious, and potentially preventable complication of percutaneous coronary intervention and is associated with adverse outcomes including an increased risk of inhospital mortality. Recent data from the National Cardiovascular Data Registry/Cath-PCI registry including 985,737 consecutive patients undergoing percutaneous coronary intervention suggest that approximately 7% expe...
Source
© 2018 Massachusetts Medical Society. Background: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. Methods: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching pl...
Source
Summary Background The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event. Methods ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate...
Source
#1John J McNeil (Florey Institute of Neuroscience and Mental Health)H-Index: 92
#2Rory Wolfe (Florey Institute of Neuroscience and Mental Health)H-Index: 82
Last. Anne M. Murray (Florey Institute of Neuroscience and Mental Health)H-Index: 45
view all 33 authors...
Abstract Background Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk. Methods From 2010 through 2014, we enrolled community-dwelling men and women in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular ...
Source
#1Meng-jie Huang (Chinese PLA General Hospital)H-Index: 8
#2Ri-bao Wei (Chinese PLA General Hospital)H-Index: 12
Last. Xiangmei Chen (Chinese PLA General Hospital)H-Index: 38
view all 9 authors...
Objectives Thromboembolic events are the major factor affecting the prognosis of patients with chronic kidney disease (CKD). Haemostatic alterations are possible causes of these complications, but their roles remain poorly characterised. In the prospective observational study, we investigated the entire coagulation process in patients with CKD to elucidate the mechanisms of their high thromboembolic risk. Methods A total of 95 patients with CKD and 20 healthy controls who met the inclusion crite...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.